Stock listing
BME:FAE Faes Farma, S.A. Acciones
Home listing (Madrid) of Faes Farma, S.A.
Follow Faes Farma, S.A. into a list and get an email when it puts out news.
Share price · BME:FAE
€4.83 EUR -0.16 (-3.2%)
Close on Nov 20, 2026
- Day range
- €4.82 – €4.91 EURNov 20, 2026
- Volume
- 122,349 sharesNov 20, 2026
- Market cap
- €1.50B EURAt the close on Nov 20, 2026 · price × 311.5M shares outstanding
- 52-week range
- €4.32 – €5.44 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €802,635 EURMedian day 128,443 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| BME:FAE · Home | €4.825 EUR | -0.16 (-3.2%) | 122,349 | €4.865 | €4.905 | €4.815 | €4.985 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · BME:FAE · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €4.825 | -0.16 | -3.2% | €4.865 | €4.905 | €4.815 | 122,349 | |
| €4.985 | -0.025 | -0.5% | €5.01 | €5.04 | €4.97 | 85,880 | |
| €5.01 | -0.07 | -1.4% | €5.05 | €5.06 | €4.90 | 129,867 | |
| €5.08 | +0.02 | +0.4% | €5.08 | €5.13 | €5.06 | 165,055 | |
| €5.06 | +0.075 | +1.5% | €4.965 | €5.08 | €4.965 | 214,687 | |
| €4.985 | -0.015 | -0.3% | €5.02 | €5.03 | €4.965 | 127,694 | |
| €5.00 | +0.085 | +1.7% | €4.965 | €5.01 | €4.935 | 187,551 | |
| €4.915 | -0.005 | -0.1% | €4.92 | €4.96 | €4.865 | 235,054 | |
| €4.92 | +0.035 | +0.7% | €4.88 | €4.93 | €4.88 | 90,384 | |
| €4.885 | -0.025 | -0.5% | €4.90 | €4.92 | €4.85 | 94,824 | |
| €4.91 | +0.015 | +0.3% | €4.94 | €4.975 | €4.88 | 207,942 | |
| €4.895 | +0.07 | +1.5% | €4.835 | €4.92 | €4.835 | 59,450 | |
| €4.825 | +0.005 | +0.1% | €4.835 | €4.865 | €4.80 | 83,322 | |
| €4.82 | -0.005 | -0.1% | €4.805 | €4.855 | €4.77 | 222,540 | |
| €4.825 | +0.05 | +1.0% | €4.785 | €4.875 | €4.78 | 317,015 | |
| €4.775 | +0.035 | +0.7% | €4.665 | €4.81 | €4.64 | 197,893 | |
| €4.74 | 0.00 | 0.0% | €4.72 | €4.785 | €4.70 | 149,494 | |
| €4.74 | +0.055 | +1.2% | €4.675 | €4.75 | €4.665 | 107,631 | |
| €4.685 | +0.05 | +1.1% | €4.62 | €4.74 | €4.62 | 107,069 | |
| €4.635 | -0.075 | -1.6% | €4.71 | €4.73 | €4.635 | 59,402 | |
| €4.71 | -0.03 | -0.6% | €4.765 | €4.765 | €4.665 | 239,372 | |
| €4.74 | -0.105 | -2.2% | €4.845 | €4.85 | €4.74 | 186,475 | |
| €4.845 | +0.165 | +3.5% | €4.69 | €4.875 | €4.69 | 147,540 | |
| €4.68 | -0.06 | -1.3% | €4.76 | €4.77 | €4.67 | 206,799 | |
| €4.74 | -0.18 | -3.7% | €4.84 | €4.905 | €4.74 | 273,746 | |
| €4.92 | -0.01 | -0.2% | €4.92 | €5.03 | €4.92 | 425,733 | |
| €4.93 | +0.13 | +2.7% | €4.815 | €4.93 | €4.815 | 139,479 | |
| €4.80 | -0.11 | -2.2% | €4.92 | €4.94 | €4.765 | 167,802 | |
| €4.91 | +0.06 | +1.2% | €4.875 | €4.92 | €4.81 | 197,220 | |
| €4.85 | +0.10 | +2.1% | €4.80 | €4.855 | €4.765 | 139,859 | |
| €4.75 | +0.005 | +0.1% | €4.685 | €4.77 | €4.685 | 118,757 | |
| €4.745 | -0.005 | -0.1% | €4.735 | €4.805 | €4.73 | 186,690 | |
| €4.75 | +0.14 | +3.0% | €4.625 | €4.755 | €4.625 | 196,910 | |
| €4.61 | +0.09 | +2.0% | €4.525 | €4.64 | €4.52 | 95,612 | |
| €4.52 | -0.03 | -0.7% | €4.54 | €4.615 | €4.52 | 102,326 | |
| €4.55 | -0.115 | -2.5% | €4.61 | €4.655 | €4.55 | 152,352 | |
| €4.665 | -0.06 | -1.3% | €4.765 | €4.79 | €4.665 | 112,273 | |
| €4.725 | -0.045 | -0.9% | €4.75 | €4.825 | €4.725 | 433,758 | |
| €4.77 | +0.08 | +1.7% | €4.715 | €4.79 | €4.715 | 173,385 | |
| €4.69 | +0.035 | +0.8% | €4.665 | €4.735 | €4.665 | 676,968 | |
| €4.655 | +0.055 | +1.2% | €4.61 | €4.705 | €4.595 | 264,153 | |
| €4.60 | -0.02 | -0.4% | €4.63 | €4.64 | €4.595 | 112,769 | |
| €4.62 | -0.035 | -0.8% | €4.66 | €4.675 | €4.62 | 206,192 | |
| €4.655 | +0.085 | +1.9% | €4.60 | €4.705 | €4.60 | 272,594 | |
| €4.57 | -0.05 | -1.1% | €4.60 | €4.68 | €4.555 | 1,095,572 | |
| €4.62 | +0.04 | +0.9% | €4.58 | €4.63 | €4.58 | 131,478 | |
| €4.58 | +0.065 | +1.4% | €4.51 | €4.595 | €4.51 | 253,978 | |
| €4.515 | +0.06 | +1.3% | €4.45 | €4.52 | €4.43 | 116,497 | |
| €4.455 | 0.00 | 0.0% | €4.45 | €4.50 | €4.45 | 76,959 | |
| €4.455 | -0.005 | -0.1% | €4.45 | €4.49 | €4.45 | 46,163 | |
| €4.46 | +0.03 | +0.7% | €4.43 | €4.48 | €4.43 | 76,288 | |
| €4.43 | -0.105 | -2.3% | €4.525 | €4.53 | €4.415 | 129,191 | |
| €4.535 | +0.045 | +1.0% | €4.50 | €4.55 | €4.48 | 78,398 | |
| €4.49 | -0.025 | -0.6% | €4.495 | €4.51 | €4.49 | 119,615 | |
| €4.515 | +0.01 | +0.2% | €4.50 | €4.53 | €4.47 | 65,051 | |
| €4.505 | +0.01 | +0.2% | €4.53 | €4.54 | €4.495 | 55,891 | |
| €4.495 | +0.015 | +0.3% | €4.49 | €4.52 | €4.465 | 63,671 | |
| €4.48 | -0.03 | -0.7% | €4.52 | €4.52 | €4.455 | 96,545 | |
| €4.51 | -0.05 | -1.1% | €4.55 | €4.56 | €4.505 | 106,094 | |
| €4.56 | -0.01 | -0.2% | €4.55 | €4.60 | €4.55 | 44,733 | |
| €4.57 | +0.025 | +0.6% | €4.52 | €4.57 | €4.515 | 83,593 | |
| €4.545 | -0.01 | -0.2% | €4.55 | €4.59 | €4.545 | 77,327 | |
| €4.555 | +0.045 | +1.0% | €4.50 | €4.57 | €4.50 | 61,430 | |
| €4.51 | -0.055 | -1.2% | €4.54 | €4.59 | €4.51 | 103,820 | |
| €4.565 | +0.015 | +0.3% | €4.53 | €4.59 | €4.53 | 70,548 | |
| €4.55 | +0.04 | +0.9% | €4.49 | €4.575 | €4.49 | 71,530 |
Splits
18 splits since 1998 · BME:FAE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 51-for-50 | Split | |
| 26-for-25 | Split | |
| 26-for-25 | Split | |
| 21-for-20 | Split | |
| 13-for-12 | Split | |
| 9-for-8 | Split | |
| 9-for-8 | Split | |
| 2-for-1 | Split | |
| 9-for-8 | Split | |
| 9-for-8 | Split | |
| 10-for-9 | Split | |
| 10-for-9 | Split | |
| 11-for-10 | Split | |
| 11-for-10 | Split | |
| 11-for-10 | Split | |
| 11-for-10 | Split | |
| 4-for-1 | Split | |
| 11-for-10 | Split |
- Ticker
- BME:FAE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Madrid
- Currency
- EUR
What changed lately
Latest news release · Jul 1, 2026
Faes Farma Signs Exclusive License And Supply Agreement For Uresco In 13 Latin American Countries
Latest deck · October 2026
9M 2026 Earnings Presentation
Earnings · 18 slides
Latest news
Faes Farma Signs Exclusive License And Supply Agreement For Uresco In 13 Latin American Countries
Jul 1, 2026
Closed €4.55 (-1.0%) on Jul 1, 2026
FAE: Revenue up 31% and net profit up 9%, with guidance reaffirmed for 2026
Apr 30, 2026
Closed €4.86 (+2.5%) on Apr 30, 2026
FAE: 23% revenue growth and major acquisitions set the stage for strong 2026 expansion
Feb 26, 2026
Closed €4.87 (-3.2%) on Feb 26, 2026
Faes Farma Approves Cash Dividend Of 0.041 Eur/Shr
Nov 21, 2025
Closed €4.59 (-0.4%) on Nov 21, 2025
Faes Farma, S.A. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 3 in the last 12 months · 12 in all · newest Jul 1, 2026 · oldest 2024
- Decks
- 32 decks · latest October 2026
Where Faes Farma, S.A. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| BME:FAE · Home listing · This page | Madrid | Spain | EUR |
| gettex:FFEA | gettex | Germany | EUR |
| Tradegate:FFEA | Tradegate | Germany | EUR |
| LS Exchange:A0MKAC | LS Exchange | Germany | EUR |
| LSIN:0K9H | LSIN | United Kingdom | EUR |
| Lang & Schwarz:A0MKAC | Lang & Schwarz | Germany | EUR |
| Stuttgart:FFEA | Stuttgart | Germany | EUR |
| Aquis:FAEE | Aquis | United Kingdom | EUR |
| Aquis:FAEE | Aquis | United Kingdom | EUR |
| Dusseldorf:FFEA | Dusseldorf | Germany | EUR |
| Frankfurt:FFEA | Frankfurt | Germany | EUR |
| Hamburg:FFEA | Hamburg | Germany | EUR |
| Munich:FFEA | Munich | Germany | EUR |
| Turquoise:FAEE | Turquoise | United Kingdom | EUR |
Valuation
P/E 11.0× against a median of 18.6×: 3rd lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €1.76B EUR
- P/E
- 11.0×
- EV/sales
- 1.7×
- EV/EBITDA
- 5.8×
- Price/book
- 1.9×
- Gross margin
- 29.9%
- Operating margin
- 24.6%
- Net margin
- 13.1%
- Debt to equity
- 0.5×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Faes Farma, S.A. · BME:FAE | US$1.65B | US$1.93B | 11.0× | 1.7× | 5.8× | 1.9× | 13.1% | 0.5× | n/a |
| Ultragenyx Pharmaceutical Inc. · NASDAQ:RARE | US$1.68B | US$2.60B | n/a | 3.6× | n/a | n/a | −71.8% | n/a | 1.35 |
| Hugel, Inc. · KRX:145020 | US$1.67B | US$1.21B | 14.1× | 3.4× | 7.1× | 2.1× | 32.9% | 0.0× | n/a |
| Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN | US$1.67B | US$1.85B | 3.7× | 1.4× | n/a | n/a | 32.9% | n/a | 0.67 |
| Caplin Point Laboratories Limited · NSE:CAPLIPOINT | US$1.66B | US$1.56B | 23.2× | 6.3× | 18.1× | 4.3× | 29.1% | 0.0× | n/a |
| AstraZeneca Pharma India Limited · NSE:ASTRAZEN | US$1.66B | US$1.60B | 86.8× | 5.7× | 59.3× | 17.5× | 6.8% | 0.0× | n/a |
| Agios Pharmaceuticals, Inc. · NASDAQ:AGIO | US$1.65B | US$1.05B | n/a | 7.4× | n/a | 1.7× | −264.8% | 0.0× | 1.10 |
| Consun Pharmaceutical Group Ltd. · HKEX:1681 | US$1.64B | US$1.07B | 10.1× | 2.1× | 5.6× | 2.3× | 31.6% | 0.1× | n/a |
| BrightGene Bio-Medical Technology Co. Ltd. Class A · SSE:688166 | US$1.63B | US$1.68B | 106× | 8.3× | n/a | 3.5× | 7.6% | 0.5× | n/a |
| Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A · SZSE:002399 | US$1.62B | US$984.0M | 57.0× | 1.3× | n/a | 0.9× | 3.7% | 0.0× | n/a |
| NATCO Pharma Limited · NSE:NATCOPHARM | US$1.62B | US$1.62B | 13.1× | 4.3× | 14.2× | 1.6× | 32.8% | 0.0× | n/a |
| Median of the others | US$1.66B | US$1.58B | 18.6× | 3.9× | 14.2× | 2.2× | 18.4% | 0.0× | 1.10 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.56 EUR · Analysts' mean
- EPS, year to Dec 2026
- 0.29 · 5 analysts
- Revenue, year to Dec 2026
- 739.6M · 4 analysts
Events
- Next results
- Feb 25, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Oct 29, 2026 · After close | +1.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 9M 2026 Earnings Presentation | Earnings | 18 slides | October 2026 |
| H1 2026 Earnings Presentation | Earnings | 20 slides | Jul 1, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 18 slides | Apr 1, 2026 |
| FY2025 Earnings Presentation | Earnings | 24 slides | 2026 |
| 9M 2025 Earnings Presentation | Earnings | 20 slides | November 2025 |
| 9M 2025 Earnings Presentation | Earnings | 20 slides | November 2025 |
| H1 2025 Earnings Presentation | Earnings | 21 slides | Jul 1, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 20 slides | May 1, 2025 |
| Investor Day (April 2025) | Investor day | 43 slides | Apr 22, 2025 |
| Investor Day (April 2025) | Investor day | 43 slides | Apr 22, 2025 |
All 32 decks
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 610.5M | 493.6M | 451.2M | 438.8M | 398.6M | 380.2M | 357.4M | 324.3M | 274.6M | 228.6M |
| Cost of revenue | 382.0M | 167.1M | 154.1M | 156.7M | 146.2M | 140.4M | 130.0M | 120.2M | 96.4M | 77.4M |
| Gross profit | 228.5M | 326.5M | 297.1M | 282.0M | 252.4M | 239.8M | 227.4M | 204.1M | 178.1M | 151.2M |
| Research and development | 4.89M | 5.80M | 5.20M | 3.72M | 3.89M | 3.25M | 4.17M | 2.82M | 3.18M | 2.59M |
| Selling, general and administrative | 91.7M | 106.0M | 33.2M | 28.9M | 27.9M | 20.1M | 21.8M | 18.4M | 19.3M | 15.0M |
| Operating income | 72.8M | 107.1M | 81.2M | 79.4M | 67.4M | 61.4M | 78.8M | 62.0M | 49.3M | 48.0M |
| Depreciation and amortization | 29.0M | 20.3M | 19.4M | 19.3M | 17.3M | 14.8M | 12.7M | 10.3M | 8.46M | 5.65M |
| EBITDA | 101.8M | 127.4M | 100.6M | 98.6M | 84.7M | 76.2M | 91.5M | 72.3M | 57.8M | 53.6M |
| Interest expense | 6.13M | 1.20M | 1.04M | 315.0K | 312.0K | 552.0K | 51.0K | 256.0K | 422.0K | 7.00K |
| Income before tax | 85.4M | 107.6M | 102.9M | 101.4M | 93.0M | 84.9M | 74.2M | 61.7M | 50.5M | 46.1M |
| Income tax | 5.75M | -3.54M | 11.2M | 12.0M | 10.5M | 11.5M | 10.1M | 9.93M | 8.31M | 9.48M |
| Net income | 79.6M | 111.4M | 91.9M | 89.5M | 82.4M | 72.5M | 64.0M | 51.6M | 42.2M | 36.6M |
| Earnings per share, basic | 0.26 | 0.36 | 0.30 | 0.29 | 0.28 | 0.25 | 0.23 | 0.19 | 0.16 | 0.14 |
| Earnings per share, diluted | 0.25 | 0.36 | 0.30 | 0.29 | 0.27 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 117.3M | 64.2M | 34.6M | 66.4M | 70.3M | 91.2M | 52.9M | 76.0M | 43.3M | 58.8M |
| Short-term investments | 12.8M | 7.92M | 13.1M | 17.7M | 3.15M | 1.93M | 1.33M | 371.0K | 70.0K | 7.18M |
| Receivables | 167.3M | 119.1M | 113.5M | 114.1M | 112.9M | 105.3M | 97.4M | 81.9M | 76.6M | 49.3M |
| Inventory | 185.0M | 142.5M | 129.0M | 115.0M | 107.5M | 91.1M | 71.5M | 59.3M | 49.9M | 38.3M |
| Current assets | 482.4M | 333.7M | 290.3M | 313.2M | 293.7M | 290.0M | 223.0M | 217.6M | 169.8M | 153.7M |
| Property, plant and equipment | 343.0M | 295.4M | 274.1M | 200.1M | 136.1M | 88.1M | 81.5M | 61.9M | 58.2M | 28.1M |
| Goodwill | 258.5M | 56.5M | 56.1M | 51.8M | 65.7M | 52.6M | 61.5M | 53.9M | 81.4M | 17.3M |
| Total assets | 1.34B | 853.1M | 776.6M | 727.1M | 645.1M | 564.1M | 493.7M | 480.8M | 430.2M | 331.2M |
| Accounts payable | 121.4M | 71.3M | 56.0M | 55.1M | 54.1M | 42.0M | 36.2M | 35.6M | 24.4M | 11.8M |
| Current liabilities | 184.9M | 103.5M | 87.3M | 94.4M | 79.3M | 84.7M | 72.3M | 103.8M | 56.5M | 37.9M |
| Long-term debt | 373.7M | 0 | 0 | 3.00K | 3.50M | 3.52M | 379.0K | 885.0K | 43.1M | 3.00K |
| Total debt | 409.9M | 7.79M | 23.9M | 32.7M | 16.4M | 13.9M | 14.8M | 52.4M | 50.0M | 1.64M |
| Total liabilities | 596.3M | 126.5M | 113.2M | 124.7M | 107.8M | 91.3M | 80.0M | 120.7M | 109.5M | 46.3M |
| Shareholders' equity | 744.8M | 725.9M | 662.4M | 601.2M | 535.8M | 471.4M | 413.0M | 359.9M | 320.2M | 284.9M |
| Shares outstanding | 313.1M | 309.3M | 310.7M | 305.9M | 304.8M | 292.0M | 273.3M | 276.2M | 268.0M | 261.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 78.5M | 115.5M | 101.0M | 107.0M | 79.6M | 78.5M | 67.6M | 59.3M | 41.7M | 49.6M |
| Capital spending | -16.1M | -33.8M | -95.8M | -75.2M | -51.5M | -25.7M | -21.4M | -12.7M | -16.6M | -12.0M |
| Free cash flow | 62.4M | 81.7M | 5.21M | 31.8M | 28.2M | 52.8M | 46.2M | 46.7M | 25.1M | 37.6M |
| Cash from investing | -299.0M | -34.2M | -97.4M | -92.4M | -83.5M | -25.8M | -34.0M | -19.6M | -83.2M | -11.5M |
| Cash from financing | 273.6M | -51.7M | -35.4M | -18.5M | -17.1M | -14.3M | -56.7M | -7.02M | 25.9M | -4.82M |
| Dividends paid | -55.7M | -48.2M | -14.6M | -18.1M | -13.7M | -12.2M | -10.3M | -7.55M | -6.28M | -5.30M |
| Share buybacks | 0 | -17.7M | 0 | 0 | -92.0K | -2.83M | -1.58M | -472.0K | -189.0K | |
| Change in cash | 53.1M | 29.6M | -31.8M | -3.84M | -21.0M | 38.4M | -23.2M | 32.8M | -15.6M | 33.3M |
Cap table
Built by 6ix from Faes Farma, S.A.’s releases
- Common shares
- 311,454,805
- Fully diluted
- 311,454,805
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 311,454,805 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 311,454,805 |
Log in to ask 6ix AI your own questions about Faes Farma, S.A.